RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Pharmaceuticals (NASDAQ:BCRX) today announced that its second
quarter 2011 financial results will be released on Thursday, August 4,
2011. BioCryst will host a conference call and webcast at 11:00 a.m.
Eastern Time to discuss the financial results and to provide an update
on the Company's programs. The call will be led by Jon
P. Stonehouse, President and Chief Executive Officer, Thomas
R. Staab, II, Senior Vice President and Chief Financial Officer and Dr.
William P. Sheridan, Senior Vice President and Chief Medical Officer.
The webcast can be accessed by logging onto www.BioCryst.com.
Please connect to the website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be needed. To participate in the conference call, please dial
1-877-303-8027 (United States) or 1-760-536-5165 (International). No
passcode is needed for the call. The audio portion of the webcast will
be archived and available for replay for at least 14 days.
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development: peramivir,
a neuraminidase inhibitor for the treatment of influenza, BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout, and forodesine, an orally-available PNP inhibitor for hematological
malignancies. Utilizing crystallography and structure-based
drug design, BioCryst continues to discover additional compounds and
to progress others through pre-clinical and early development to address
the unmet medical needs of patients and physicians. For more
information, please visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
Robert Bennett, 919-859-7910
Source: BioCryst Pharmaceuticals
News Provided by Acquire Media